New loss of smell and taste: Uncommon symptoms in COVID-19 patients on Nord Franche-Comte cluster, France.
Anosmia
Clinical features
Coronavirus disease 2019
Dysgeusia
Symptoms
Journal
International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933
Informations de publication
Date de publication:
Nov 2020
Nov 2020
Historique:
received:
18
04
2020
revised:
31
07
2020
accepted:
04
08
2020
pubmed:
11
8
2020
medline:
2
12
2020
entrez:
11
8
2020
Statut:
ppublish
Résumé
New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients. We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comté Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases. Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(±2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (±5, [1-21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0-8.6] vs 5.3 [2.1-8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths. Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.
Sections du résumé
BACKGROUND
BACKGROUND
New loss of smell or taste was not included as common symptoms of COVID-19 until March 2020 when the pandemic started in Western countries. We want to describe the prevalence and features of anosmia and dysgeusia in COVID-19 patients.
METHODS
METHODS
We retrospectively investigated the clinical features of confirmed cases of COVID-19 in Nord Franche-Comté Hospital, Trevenans, France, between March, 1st and March, 14th 2020. We used SARS-CoV-2 real time RT-PCR in respiratory samples to confirm the cases.
RESULTS
RESULTS
Of 70 patient enrolled, the mean age was 57.0 years and 29 patients (41%) were men. Median Charlson comorbidity index was 1.70(±2.5). Twenty-seven (39%) patients had pneumonia. Fatigue (93% [65]), cough (80% [55]) and fever (77% [54]) were the three main symptoms. Neurologic symptoms were present in more than half of the patients: anosmia (53% [37]) and dysgeusia (48% [34]). The mean duration of anosmia was 7.4 (±5, [1-21]) days, 51% (36/70) recovered before 28 days of evolution. Only one patient with anosmia had not recovered at the end of the follow-up. Patients with anosmia had less often a pneumonia (10/37 vs 17/33, p = 0.036), were less often hospitalized (13/37 vs 20/33, p = 0.033) and needed less often oxygen therapy (6/37 vs 17/33, p = 0.002) than patients without anosmia. There were no statistically differences for viral load between patients with anosmia and patients without anosmia (5.5 [2.0-8.6] vs 5.3 [2.1-8.5] log copies/ml respectively, p = 0.670). The fatality of COVID-19 in our study was 6% with four deaths.
CONCLUSIONS
CONCLUSIONS
Anosmia and dysgeusia are present in half of COVID-19 patients. The mean duration of anosmia was 7 days and the outcome seems favorable in less than 28 days.
Identifiants
pubmed: 32771635
pii: S1201-9712(20)30637-8
doi: 10.1016/j.ijid.2020.08.012
pmc: PMC7410813
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
117-122Informations de copyright
Copyright © 2020 The Author(s). Published by Elsevier Ltd.. All rights reserved.
Références
JAMA. 2020 Mar 17;323(11):1061-1069
pubmed: 32031570
Clin Infect Dis. 2020 Jul 28;71(15):769-777
pubmed: 32176772
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
Acta Otolaryngol. 1995 Jan;115(1):88-92
pubmed: 7762392
J Med Virol. 2020 Jul;92(7):703-704
pubmed: 32352575
Am J Rhinol Allergy. 2012 May-Jun;26(3):204-8
pubmed: 22643947
Int Forum Allergy Rhinol. 2020 Jan;10(1):7-14
pubmed: 31899859
Rhinology. 1994 Sep;32(3):113-8
pubmed: 7530857
Laryngoscope. 2007 Feb;117(2):272-7
pubmed: 17277621
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
JAMA. 2020 Apr 7;323(13):1239-1242
pubmed: 32091533
Laryngoscope. 2006 Mar;116(3):436-9
pubmed: 16540905
Euro Surveill. 2020 Feb;25(6):
pubmed: 32070465
Clin Infect Dis. 2020 Jul 28;71(15):706-712
pubmed: 32109279
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
Allergy Asthma Proc. 2010 May-Jun;31(3):185-9
pubmed: 20615320
Chem Senses. 2016 Jan;41(1):69-76
pubmed: 26487703
Euro Surveill. 2020 Jan;25(3):
pubmed: 31992387
Am J Rhinol Allergy. 2014 Sep-Oct;28(5):419-22
pubmed: 25198029
N Engl J Med. 2020 Feb 20;382(8):727-733
pubmed: 31978945
Int J Infect Dis. 2020 Aug;97:208-211
pubmed: 32535294
Clin Microbiol Infect. 2019 Sep;25(9):1147-1153
pubmed: 30703528
Rhinology. 2011 Dec;49(5):519-24
pubmed: 22125781
Infection. 2021 Apr;49(2):361-365
pubmed: 32410112
Lancet Respir Med. 2020 May;8(5):475-481
pubmed: 32105632
Am J Rhinol. 2006 Jan-Feb;20(1):101-8
pubmed: 16539304